Patents by Inventor Anna Marie Skalka

Anna Marie Skalka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11389455
    Abstract: The disclosure generally relates to compounds, compositions, and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: July 19, 2022
    Assignee: Institute for Cancer Research
    Inventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
  • Publication number: 20210113570
    Abstract: The disclosure generally relates to compounds, compositions, and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: December 30, 2020
    Publication date: April 22, 2021
    Inventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
  • Patent number: 10888564
    Abstract: The disclosure generally relates to compounds of formulas (I) and (II)7 including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: January 12, 2021
    Assignee: Institute for Cancer Research
    Inventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
  • Publication number: 20190381054
    Abstract: The disclosure generally relates to compounds of formulas (I) and (II)7 including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 19, 2019
    Inventors: Mark D. ANDRAKE, Anna Marie SKALKA, George W. Merkel
  • Patent number: 9533040
    Abstract: Methods to inhibit the formation of retrovirus integrase reaching dimers, to dissociate retrovirus integrase reaching dimers, and to stabilize retrovirus integrase reaching dimers in a conformation in which retrovirus DNA-to host cell DNA integration activity of the integrase is inhibited are provided. Methods for treating a retrovirus infection, which target retrovirus integrase reaching dimer formation and/or stability are also provided.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 3, 2017
    Assignee: Institute for Cancer Research
    Inventors: Anna Marie Skalka, Mark Andrake, Ravi Shankar Bojja
  • Publication number: 20130280271
    Abstract: Methods to inhibit the formation of retrovirus integrase reaching dimers, to dissociate retrovirus integrase reaching dimers, and to stabilize retrovirus integrase reaching dimers in a conformation in which retrovirus DNA-to host cell DNA integration activity of the integrase is inhibited are provided. Methods for treating a retrovirus infection, which target retrovirus integrase reaching dimer formation and/or stability are also provided.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 24, 2013
    Inventors: Anna Marie Skalka, Mark Andrake, Ravi Shankar Bojja
  • Publication number: 20110172107
    Abstract: A high throughput RNAi-based assay for identify factors involved in maintaining epigenetic silencing is disclosed. The assay measures reactivation of a silent reporter gene in cells, resulting from RNAi-based knockdown in target mRNA. RNAi-based screening of these silent reporter cells has identified known enzymes that place or remove epigenetic marks on histones, as well as non-enzymatic proteins that function in silencing or in transfer of marks during S-phase. In addition, the screen has been used to identify a number of novel gene products involved in epigenetic silencing, which are also disclosed.
    Type: Application
    Filed: April 30, 2009
    Publication date: July 14, 2011
    Applicant: FOX CHASE CANCER CENTER
    Inventors: Richard A. Katz, Anna Marie Skalka
  • Publication number: 20110086423
    Abstract: Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
    Type: Application
    Filed: June 14, 2010
    Publication date: April 14, 2011
    Inventors: Rene Daniel, Anna Marie Skalka, Gary D. Kao, Giuseppe Nunnari, Roger J. Pomerantz
  • Patent number: 7736848
    Abstract: Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: June 15, 2010
    Assignee: Fox Chase Cancer Center
    Inventors: Rene Daniel, Anna Marie Skalka, Gary D. Kao, Giuseppe Nunnari, Roger J. Pomerantz
  • Patent number: 6150511
    Abstract: The present invention provides novel chimeric and fusion proteins useful for facilitating site-specific integration of foreign DNA into a host genome. The chimeric enzymes of the invention comprise a DNA binding moiety fused to a retroviral integrase moiety, preferably at the precise N- or C-terminus. Nucleic acids encoding these fusion proteins can be incorporated into standard retroviral vectors, or can be provided as purified proteins. They are capable of exerting the activities of a wildtype retroviral integrase, including processing retroviral DNA termini, nicking double-stranded DNA and integrating a DNA molecule with processed retroviral termini into another DNA strand.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: November 21, 2000
    Assignee: Fox Chase Cancer Center
    Inventors: Richard A. Katz, Anna Marie Skalka